Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2023-04-21 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于召开2022年度暨2023年第一季度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling of an investor earnings explanation meeting for the 2022 annual results and 2023 first quarter results. It provides details about the meeting time, location, participants, and how investors can participate and ask questions. It does not contain actual financial statements or substantive financial data but rather informs about the upcoming event where such data will be discussed. The document length is short (1612 characters) and it serves as a notice for an earnings call or investor presentation rather than the transcript or the report itself. Therefore, it fits best under the category of Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, specifically an earnings explanation meeting announcement.
2023-04-21 Chinese
西部证券股份有限公司关于圣湘生物科技股份有限公司2022年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度持续督导跟踪报告" (2022 Annual Continuous Supervision Follow-up Report) issued by a sponsoring institution (西部证券股份有限公司) for a listed company (圣湘生物科技股份有限公司). It references regulatory frameworks related to securities issuance, listing rules, and continuous supervision requirements by the Shanghai Stock Exchange. The content includes detailed supervisory activities, risk disclosures, financial data, and compliance status for the year 2022. This type of report is a regulatory continuous supervision report by the sponsor post-IPO, which is a form of audit or regulatory oversight report rather than a full annual report or earnings release. It is not a simple announcement or certification but a substantive report with detailed findings and financial data. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit or regulatory supervision reports excluding full annual reports. FY 2022
2023-04-18 Chinese
圣湘生物科技股份有限公司监事会关于《公司2023年限制性股票激励计划（草案）》的核查意见
Regulatory Filings Classification · 90% confidence The document is a supervisory board's opinion on the company's 2023 restricted stock incentive plan draft. It discusses compliance with laws and regulations, qualifications of incentive recipients, and governance implications. It is not a financial report, earnings release, or regulatory filing per se, but rather a formal opinion related to a stock incentive plan. This fits best under Regulatory Filings (RNS) as it is a compliance and governance-related disclosure that does not fit other specific categories like Capital/Financing Update or Remuneration Information. The document length is short and it is not an announcement of a report publication, so RPA is not appropriate.
2023-04-18 Chinese
圣湘生物科技股份有限公司关于独立董事公开征集委托投票权的公告
Proxy Solicitation & Information Statement Classification · 100% confidence The document is an announcement by the company 圣湘生物科技股份有限公司 regarding the public solicitation of proxy voting rights by an independent director for the upcoming 2022 Annual General Meeting (AGM) scheduled on May 9, 2023. It details the solicitation process, the independent director's background, the voting agenda related to the 2023 restricted stock incentive plan, and instructions for shareholders to submit proxy votes. The document does not contain financial statements or results but is focused on the proxy solicitation for voting at the AGM. This fits the category of Proxy Solicitation & Information Statement (PSI).
2023-04-18 Chinese
圣湘生物科技股份有限公司关于2022年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the company's fundraising (募集资金) management and actual usage for the fiscal year 2022. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and includes detailed financial figures on the amount raised, usage, balances, and investment projects. It also includes auditor and sponsor opinions on the fundraising usage compliance. The document is titled as a "专项报告" (special report) on fundraising funds storage and usage for 2022, which aligns with a specialized report on capital/financing activities rather than a general annual report or earnings release. The content focuses exclusively on fundraising capital management and usage, consistent with the Capital/Financing Update category. The document length is substantial (15,000 characters), containing actual financial data and analysis, not merely an announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-04-18 Chinese
上海信公轶禾企业管理咨询有限公司关于圣湘生物科技股份有限公司2023年限制性股票激励计划（草案）之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" regarding the 2023 Restricted Stock Incentive Plan (Draft) of Shengxiang Bio-Technology Co., Ltd. It is a detailed report prepared by an independent financial advisor analyzing the feasibility, compliance, and financial implications of the company's stock incentive plan. The content includes legal and regulatory compliance checks, financial accounting treatment, impact on shareholders, and detailed plan terms. This type of report is a standalone audit or advisory report related to a specific corporate action (stock incentive plan), not a full annual or quarterly report, nor a simple announcement or presentation. It fits the category of an Audit Report / Information (AR) as it provides an independent financial advisor's audit and opinion on the stock incentive plan, including compliance with laws and accounting standards. FY 2023
2023-04-18 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.